Regeneron Pharmaceuticals, Inc.
Genome-Based Methods For Reducing Cardiovascular Risk
Last updated:
Abstract:
The present disclosure provides methods of reducing cardiovascular risk by administration of a PCSK9 inhibitor to patients having a genetic profile associated with response to PCSK9 inhibitor therapy.
Status:
Application
Type:
Utility
Filling date:
16 May 2020
Issue date:
7 Jan 2021